The 2009 Edition Directory includes a total of 2,151 medicines and became
effective throughout the PRC on
The 23 medicines treat a variety of common indications and diseases and make up approximately 70% of Tianyin's total revenues for the fiscal year 2009. Among 23 medicines produced by Tianyin, 8 medicines are classified as Category A and 15 medicines are classified as Category B.
"We are very pleased to have such a broad base of our product portfolio included in the 2009 National Insurance Directory. We expect the weighted average price of these medicines will not be affected and sales volume for these products will grow significantly, thus creating positive incremental revenue and earnings growth for 2010 and beyond," Dr. Jiang, Chairman and CEO of Tianyin Pharmaceutical Co., Inc., commented. "Inclusion in this Directory will drive demand as consumers benefit from the government's desire to bring better healthcare to the masses. We believe this will provide another growth conduit for Tianyin as we leverage our expanded production capacity, respected brand name and broad distribution base to capitalize on this significant growth opportunity."
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional Chinese
Medicine ("TCM") in China. It was established in 1994 and acquired by the
current management team in
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
For more information, please contact: For the Company: Allen Tang, Ph.D., MBA, Assistant to the CEO China Tel: +86-158-2122-5642 Email: Allen.email@example.com Investors: Mr. Matthew Hayden, HC International Tel: +1-561-245-5155 Email: firstname.lastname@example.org
SOURCE Tianyin Pharmaceutical Co., Inc.